Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, today announced the successful acquisition of a first-in-class novel TLR-2 antagonist molecule from Eos Therapies, ...
Primary tumor sites included the pancreas (15 patients), ileum (6 patients), lung (3 patients ... A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with ...